LAUSR

Simple Summary There is a paucity of evidence assessing the impact of bile duct stenting at the time of EUS-guided tissue sampling, either using fine-needle biopsy (EUS-FNB) or fine-needle aspiration (EUS-FNA) in patients with head of pancreas (HOP) masses. Our main aim was to assess the diagnostic accuracy of endoscopic ultrasound-guided tissue acquisition (EUS-TA) in patients with or without concurrent bile duct stents. Pooled accuracy was not statistically different between both patient subsets. However, we found that, compared to plastic stents, patients with biliary metal stents had a significantly lower yield of EUS-TA for pancreatic head lesions. Abstract There is a paucity of evidence regarding whether biliary stents influence endoscopic ultrasound-guided tissue acquisition using either fine-needle biopsy (EUS-FNB) or fine-needle aspiration (EUS-FNA), among patients with head of pancreas (HOP) lesions. We aimed at assessing the diagnostic accuracy of endoscopic ultrasound-guided tissue sampling in patients with or without bile duct stents. A total of seven studies with 2458 patients were included. The main aim was to assess overall pooled diagnostic accuracy. A pairwise meta-analysis was performed using a random effects model. Outcomes were expressed as odds ratios (ORs) with 95% confidence intervals (CIs). We found that pooled accuracy was 85.4% (CI 78.8–91.9) and 88.1% (CI 83.3–92.9) in patients with and without stents, respectively. There was no statistically significant difference between the two (OR 0.74; p = 0.07). Furthermore, patients with metal stents demonstrated a significant difference (OR 0.54, 0.17–0.97; p = 0.05), which was not seen with plastic stents. EUS-FNB showed poorer diagnostic accuracy with concurrent biliary stenting (OR 0.64, 0.43–0.95; p = 0.03); however, the same was not observed with EUS-FNA. Compared to plastic stents, metal biliary stenting further impacted the diagnostic accuracy of EUS-guided tissue acquisition for pancreatic head lesions. There was no difference in the rate of procedure-related adverse events between the stent and no-stent groups.